MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues - {财报副标题}

Management Commentary

MLYS -performance metrics {随机描述} {随机描述} Management highlighted continued advancement of the company’s lead candidate, lorundrostat (MLS-101), a highly selective aldosterone synthase inhibitor being developed for hypertension and chronic kidney disease. In Q1, enrollment progressed in the Phase 2 pivotal trial for uncontrolled hypertension, with topline data expected in the second half of 2026. The firm also initiated a Phase 2 study for lorundrostat in treatment-resistant hypertension. Research and development expenses totaled $29.2 million, up from $18.4 million in the year-ago period, driven by clinical trial activities and manufacturing scale-up. Selling, general and administrative costs were $10.1 million, reflecting increased personnel and infrastructure to support upcoming registration efforts. At quarter-end, cash, cash equivalents and marketable securities stood at $216 million, which management believes will fund operations into mid-2027. No segment performance or revenue was reported, as the company remains fully focused on clinical development. MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}

Forward Guidance

MLYS -performance metrics {随机描述} {随机描述} Mineralys did not provide explicit revenue guidance, but management reiterated plans to submit a New Drug Application for lorundrostat in uncontrolled hypertension, pending Phase 2 success. The company anticipates completing the ongoing pivotal trial in the first half of 2026, with a potential NDA submission in the fourth quarter. Beyond hypertension, the company may explore additional indications, including heart failure with preserved ejection fraction, based on preclinical data. Key risk factors include: the possibility of longer-than-expected patient enrollment, uncertainty around regulatory pathways for aldosterone synthase inhibitors, and potential competitive advances from similar programs at Novo Nordisk and AstraZeneca. Management also highlighted potential volatility in cash runway if clinical timelines shift or if further financing is required, though current liquidity is deemed adequate for near-term milestones. MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}

Market Reaction

MLYS -performance metrics {随机描述} {随机描述} Shares of MLYS fell 1.26% on the earnings release, trading at approximately $44.50 (based on recent levels). The modest decline suggests the market largely expected the narrower loss, given the minimal surprise. Analysts from Piper Sandler and Oppenheimer reiterated Overweight ratings, noting the potential of lorundrostat to address a large unmet need in resistant hypertension. However, the lack of near-term revenue catalysts and the early-stage nature of the pipeline may keep the stock range-bound until pivotal data readout. Investors should monitor updates on enrollment speed and any safety signals observed in the ongoing trials. The next key catalyst is likely the interim analysis from the pivotal study, expected by mid-year. Overall, MLYS remains a binary-risk story tied to clinical execution. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}MLYS Q1 2026 Earnings: Narrow Beat on Losses as Clinical Pipeline Progress Continues {随机描述}{随机描述}